Trastuzumab deruxtecan (DS-8201a), a HER2-targeting drug, enhanced PD-L1 expression and CD8+ T cell infiltration in breast cancer, which DS-8201a also had synergistic effect with anti-PD-1 therapy [250]. Here, ERBB2 is linked to breast carcinoma.